Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence
Executive Summary
In a recent presentation on evidence-based reimbursement and personalized medicine, a Novartis executive highlights Medicare Part B contractor Palmetto GBA’s molecular diagnostic reimbursement initiative as one to watch.
You may also be interested in...
Medicare Part B: Commentary By CMS Officials
CMS officials Jonathan Blum, Louis Jacques and Tamara Jensen addressed a number of Medicare Part B-related topics of interest to the biopharmaceutical industry at the FDA/CMS Summit, including reimbursement for high-priced oncology drugs, coverage with evidence development and national coverage determinations.
Molecular Dx Reimbursement: Medicare Contractor Seeks Tighter Controls
The Medicare contractor that handles claims for California and several other states is taking steps to enhance its control over reimbursement of molecular diagnostic tests.
With Genoptix, Novartis Continues Its Diagnostics Build Up
Novartis is building a molecular diagnostics business, which can support its pharmaceutical business's aggressive expansion in targeted therapies.